Development of USPIO-DM1-5D3-CF750: An image-guided targeted drug delivery system for prostate cancer therapy
Sudath Hapuarachchige1,2, Ge Si1,3, Catherine Foss1, Cyril Barinka4, and Dmitri Artemov1,2
1Department of Radiology and Radiological Science, The Johns Hopkins School of Medicine, Baltimore, MD, United States, 2Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States, 3Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, MD, United States, 4Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, Vestec, Czech Republic
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancers (PC) compared to normal tissues. Hence, PSMA can be used as a diagnostic biomarker and biological target to deliver drugs in PC therapy. In this study, we have conjugated ultra-small superparamagnetic iron oxide nanoparticles with mertansine (DM1), a chemotherapeutic drug, novel anti-PSMA 5D3 antibody, and NIR CF-750 fluorophore. This multimodality image-guided drug delivery system was evaluated in PC mouse models using in vivo fluorescent imaging and MRI at 9.4T. Promising results encourage further development of targeted image-guided drug delivery platforms for PC therapy.
This abstract and the presentation materials are available to members only;
a login is required.